# A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

> **NCT04214951** · — · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 100 (actual)

## Conditions studied

- Corticosteroid-resistant or Relapsed ITP

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Recombinant human thrombopoietin (rh-TPO)

## Key facts

- **NCT ID:** NCT04214951
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04214951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04214951, "A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04214951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*